Company Directory - Amedisys Inc.
Company Details - Amedisys Inc.
Amedisys Inc.
WebsiteBaton Rouge, United States
Amedisys Inc. is a leading home health care company based in Baton Rouge, Louisiana, serving over 332,000 patients across the United States. The company provides a range of services including home health care, hospice care, and personal care.
CCI Score
CCI Score: Amedisys Inc.
-42.87
0.02%
Latest Event
DOJ Blocks Merger Amid Allegations of Unethical Practices
On November 25, 2024, the U.S. Department of Justice, along with several state Attorneys General, filed a civil antitrust lawsuit to block UnitedHealth Group's $3.3 billion acquisition of Amedisys Inc. The lawsuit alleges that the merger would harm competition in the healthcare market and that Amedisys violated the Hart-Scott-Rodino Act by failing to disclose millions of documents and deleting records. This action is aimed at preventing market consolidation that could adversely affect patient care, competitive wages, and transparency in business practices.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
Amedisys Inc. is currently rated as a Toadie.
Latest Events
- NOV252024
On November 25, 2024, the U.S. Department of Justice, along with several state Attorneys General, filed a civil antitrust lawsuit to block UnitedHealth Group's $3.3 billion acquisition of Amedisys Inc. The lawsuit alleges that the merger would harm competition in the healthcare market and that Amedisys violated the Hart-Scott-Rodino Act by failing to disclose millions of documents and deleting records. This action is aimed at preventing market consolidation that could adversely affect patient care, competitive wages, and transparency in business practices.
-70
Business Practices and Ethical Responsibility
April 2
Amedisys is accused of unethical business practices including failure to disclose required merger documents and deleting critical records during the antitrust review process. Such actions undermine transparency and ethical responsibility, a key indicator of corporate behavior that could facilitate authoritarian market consolidation.
-80
Economic and Structural Influence
April 2
The potential merger, had it proceeded, would have considerably increased market concentration in home health and hospice care, threatening competitive conditions, fair wages, and improved services for vulnerable populations. The DOJ’s intervention reflects concerns over Amedisys’ role in facilitating economic consolidation that can undermine the welfare of both patients and healthcare workers.
- NOV202024
The U.S. Department of Justice, along with state attorneys general from Maryland, Illinois, New Jersey, and New York, filed a civil antitrust lawsuit to block UnitedHealth Group’s $3.3 billion acquisition of Amedisys. The suit argues that the merger would significantly reduce competition in home health, hospice, and nurse labor markets, and also alleges that Amedisys falsely certified compliance with the Hart-Scott-Rodino Act, failing to produce or disclosing key documents.
-90
Business Practices and Ethical Responsibility
April 2
Amedisys is accused of compromising its ethical business practices by allegedly falsifying compliance documentation under the HSR Act. This misconduct not only undermines transparency and accountability but also sets the stage for a merger that could harm patients, insurers, and health care workers by reducing competition and consolidating market power.
-70
Economic and Structural Influence
April 2
The proposed merger, if allowed, would concentrate market power in the home health and hospice sectors, threatening competition across numerous local markets. This consolidation could adversely impact vulnerable patients and the labor force, thereby reinforcing economic structures that favor authoritarian market control.
- NOV142024
The DOJ filed a lawsuit to block UnitedHealth Group's takeover of Amedisys, alleging the deal is anticompetitive and illegal. The suit highlights concerns over potential market consolidation, negative impacts on patients, and diminished competition leading to lower wages and compromised care quality, along with alleged violations of the HSR Act.
-60
Business Practices and Ethical Responsibility
April 2
Amedisys is implicated in a merger that faces serious antitrust allegations. The DOJ complaint points to alleged HSR Act violations and a broader strategy that undermines transparent business practices and fair labor conditions, potentially harming patients and workers through reduced competition.
DOJ Sues To Block 'Anticompetitive and Illegal' UnitedHealth Group-Amedisys Deal
-40
Economic and Structural Influence
April 2
The merger would significantly consolidate market power in the home health sector, risking the elimination of robust competition that currently supports better wages and care quality. Such economic consolidation can lead to a dominant market structure that undermines both patient choice and workers' rights.
DOJ Sues To Block 'Anticompetitive and Illegal' UnitedHealth Group-Amedisys Deal
- NOV142024
On November 14, 2024, the Department of Justice, along with state Attorneys General, filed a civil antitrust lawsuit to block UnitedHealth Group's $3.3 billion acquisition of Amedisys. The complaint argues that the merger would harm competition critical for maintaining affordable, high-quality care for vulnerable patients and nurses. The filing also alleges that Amedisys falsely certified its compliance under the Hart-Scott-Rodino Act by failing to produce required documents, raising concerns about the company's ethical business practices.
+20
Public and Political Behavior
April 2
Amedisys leadership, including its former CEO and current board chairman, has acknowledged that maintaining competition with UnitedHealth is crucial to drive quality improvements in patient care and protect healthcare workers. This recognition supports a democratic and diverse market structure.
Justice Department Sues to Block UnitedHealth Group's Purchase of Amedisys
-40
Business Practices and Ethical Responsibility
April 2
The DOJ complaint alleges that Amedisys falsified its compliance with the Hart-Scott-Rodino Act by failing to produce millions of required documents, suggesting potential corporate malfeasance and a disregard for ethical business practices. This issue raises significant concerns about the company's accountability.
Justice Department Sues to Block UnitedHealth Group's Purchase of Amedisys
- JAN012024
Amedisys Inc spent $840,000 on lobbying in 2024, as reported by OpenSecrets, raising concerns about the potential use of corporate political spending to influence policy and weaken democratic accountability.
-50
Political Contributions and Lobbying Efforts
April 2
The $840,000 lobbying expenditure by Amedisys Inc demonstrates significant corporate political spending that can contribute to undue influence over policy-making. Such practices raise alarms in terms of democratic accountability and may indirectly empower authoritarian approaches if corporate interests dominate policymaking.
- JAN012023
A PAC profile from OpenSecrets shows that Amedisys Inc raised $149,149 during the 2023-2024 election cycle. This modest figure reflects the company’s engagement in the political arena via its corporate PAC, highlighting how corporate funds can play a role in influencing political processes.
-10
Political Contributions and Lobbying Efforts
April 2
The PAC data indicates that Amedisys Inc raised $149,149 in the 2023-2024 cycle. While the amount is relatively modest, from an anti-fascist perspective any corporate political spending is concerning as it reinforces the influence of corporate money in politics. Such activities contribute to the entrenchment of systems that can amplify corporate influence at the expense of democratic accountability.
Alternatives
Corporation
33.84
Lubbock, United States
9.69
New York, United States
-25.62
London, United Kingdom
3.38
Corporation
-11.71
Corporation
-51.82
Baltimore, United States
-20.95
Salt Lake City, USA
45.93
London, England
29.86
Canada
0.09
Corporate Financials
- Revenue
- 2022
- $540.00M
- Total Assets
- 2022
- $1.00B
- Operating Income
- 2022
- $70.00M
- Total Equity
- 2022
- $650.00M
Industries
- 621610
- Home Health Care Services
- 621999
- All Other Miscellaneous Ambulatory Health Care Services
- 623110
- Nursing Care Facilities (Skilled Nursing Facilities)